Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs
Aim of investigation. To study the role of serological markers of hepatitis B virus infection: antibodies to hepatitis B virus cor-antigen (anti-HВcor IgG) in progressing liver damage at patients with persistent hepatitis C virus infection.Material and methods. For the first time in the large group...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2011-03-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1385 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860196713168896 |
|---|---|
| author | Ye. N. German M. V. Mayevskaya O. I. Andreytseva V. T. Ivashkin A. V. Chzhao A. G. Serova G. V. Mikhaylovskaya I. Yu. Pirogova |
| author_facet | Ye. N. German M. V. Mayevskaya O. I. Andreytseva V. T. Ivashkin A. V. Chzhao A. G. Serova G. V. Mikhaylovskaya I. Yu. Pirogova |
| author_sort | Ye. N. German |
| collection | DOAJ |
| description | Aim of investigation. To study the role of serological markers of hepatitis B virus infection: antibodies to hepatitis B virus cor-antigen (anti-HВcor IgG) in progressing liver damage at patients with persistent hepatitis C virus infection.Material and methods. For the first time in the large group of patients (2934) significant prevalence of serological markers of hepatitis B and C viruses among patients of versatile clinic was demonstrated.Results. According to actual data it was proved, that antibodies to cor-antigen of hepatitis B virus at patients with persistent hepatitis С virus infection do not alter biochemical activity and severity of liver disease. With application of prognostic models tendency to higher risk of end-stages of liver disease development at patients with persistent hepatitis B virus infection and anti-HBcor IgG in blood serum was revealed. The potential of application of liver graft from the donor with serological profile anti-HCV/anti-HBcor IgG (at absence of other contraindications) is proved for certain groups of recipients. Arguments for revision of criteria for selection of donor of organs were presented for prophylaxis of de novo hepatitis B at the recipient (so-called de novo graft infection – HBsAg appearance at the recipient at absence of viral infection markers before operation). |
| format | Article |
| id | doaj-art-5ec289240a8748929f96f3cb0271bd97 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2011-03-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-5ec289240a8748929f96f3cb0271bd972025-02-10T16:14:31ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732011-03-012121421939Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organsYe. N. GermanM. V. MayevskayaO. I. AndreytsevaV. T. IvashkinA. V. ChzhaoA. G. SerovaG. V. MikhaylovskayaI. Yu. PirogovaAim of investigation. To study the role of serological markers of hepatitis B virus infection: antibodies to hepatitis B virus cor-antigen (anti-HВcor IgG) in progressing liver damage at patients with persistent hepatitis C virus infection.Material and methods. For the first time in the large group of patients (2934) significant prevalence of serological markers of hepatitis B and C viruses among patients of versatile clinic was demonstrated.Results. According to actual data it was proved, that antibodies to cor-antigen of hepatitis B virus at patients with persistent hepatitis С virus infection do not alter biochemical activity and severity of liver disease. With application of prognostic models tendency to higher risk of end-stages of liver disease development at patients with persistent hepatitis B virus infection and anti-HBcor IgG in blood serum was revealed. The potential of application of liver graft from the donor with serological profile anti-HCV/anti-HBcor IgG (at absence of other contraindications) is proved for certain groups of recipients. Arguments for revision of criteria for selection of donor of organs were presented for prophylaxis of de novo hepatitis B at the recipient (so-called de novo graft infection – HBsAg appearance at the recipient at absence of viral infection markers before operation).https://www.gastro-j.ru/jour/article/view/1385latent hbv-infectionanti-hвcorigganti-hcvliver transplantation |
| spellingShingle | Ye. N. German M. V. Mayevskaya O. I. Andreytseva V. T. Ivashkin A. V. Chzhao A. G. Serova G. V. Mikhaylovskaya I. Yu. Pirogova Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs Российский журнал гастроэнтерологии, гепатологии, колопроктологии latent hbv-infection anti-hвcorigg anti-hcv liver transplantation |
| title | Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs |
| title_full | Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs |
| title_fullStr | Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs |
| title_full_unstemmed | Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs |
| title_short | Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs |
| title_sort | treatment of end stages of liver disease in outcome of persistent hepatitis c virus infection at deficiency of donor organs |
| topic | latent hbv-infection anti-hвcorigg anti-hcv liver transplantation |
| url | https://www.gastro-j.ru/jour/article/view/1385 |
| work_keys_str_mv | AT yengerman treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT mvmayevskaya treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT oiandreytseva treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT vtivashkin treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT avchzhao treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT agserova treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT gvmikhaylovskaya treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans AT iyupirogova treatmentofendstagesofliverdiseaseinoutcomeofpersistenthepatitiscvirusinfectionatdeficiencyofdonororgans |